Generation bio announces recent business highlights and first quarter 2024 financial results

- oral presentation at asgct described selective, high levels of therapeutic transgene delivery to t cells in vivo by cell-targeted lipid nanoparticle (ctlnp)

GBIO Ratings Summary

GBIO Quant Ranking